Grace Therapeutics, Inc. Payments of Stock Issuance Costs
Grace Therapeutics, Inc. (GRCE) reported Payments of Stock Issuance Costs of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-13
- Grace Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- Grace Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00.
- Grace Therapeutics, Inc. payments of stock issuance costs for fiscal 2026 was $327.00K, a 66.18% decline from fiscal 2025.
- Grace Therapeutics, Inc. payments of stock issuance costs for fiscal 2025 was $967.00K, a 496.91% increase from fiscal 2024.
- Grace Therapeutics, Inc. payments of stock issuance costs for fiscal 2024 was $162.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $0.00 derived: sum of 2 quarters · filed 2026-06-18 | $0.00 derived: sum of 3 quarters · filed 2026-06-18 | $327.00K 10-K · filed 2026-06-18 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $327.00K 10-Q · filed 2026-02-12 | $1.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $327.00K 10-Q · filed 2025-11-13 | $1.29M derived: sum of 3 quarters · filed 2026-08-13 | $1.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $327.00K 10-Q · filed 2026-08-13 | $1.29M derived: sum of 2 quarters · filed 2026-08-13 | $1.29M derived: sum of 3 quarters · filed 2026-08-13 | $1.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $967.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $967.00K derived: sum of 2 quarters · filed 2026-06-18 | $967.00K derived: sum of 3 quarters · filed 2026-06-18 | $967.00K 10-K · filed 2026-06-18 |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $162.00K 10-K · filed 2025-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |